Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2027-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. A predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. This model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. By enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma

NCT03692533

Renal Cell Carcinoma

UNKNOWN NA

Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study

NCT06883565

Renal Cell Carcinoma (RCC)

COMPLETED

A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma

NCT06658587

Cholangiocarcinoma

NOT_YET_RECRUITING

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650

Kidney Cancer

COMPLETED

Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer

NCT05285579

Renal Cell Carcinoma Renal Cancer Renal Cancer Metastatic

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Carcinoma Serology Autoantibody

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathological diagnosis of ccRCC;
* Availability of complete clinical, pathological, and follow-up data;
* Sufficient preoperative serum available for collection;
* Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis;
* At least one post-treatment follow-up/efficacy evaluation.

Exclusion Criteria

* Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions;
* Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies;
* Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity;
* Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes